Jazz Pharmaceuticals

Explore the latest insights on Jazz Pharmaceuticals and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Jazz Pharmaceuticals’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about Jazz Pharmaceuticals, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Jazz Pharmaceuticals please access Flcube.com

BioPartners X Signs RMB 227 Million Technology Transfer Deal with CAMS for CD132 Autoimmune Antibody
CompanyDeals

BioPartners X Signs RMB 227 Million Technology Transfer Deal with CAMS for CD132 Autoimmune Antibody

BioPartners X announced that it has entered into a technology transfer agreement with the Hospital of Dermatology, Chinese Academy of Medical Sciences (CAMS) for an innovative CD132‑targeting monoclonal antibody, with…

Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory Form Joint Venture to Develop 25‑Hydroxycholesterol – A Prodrug‑Class Broad‑Spectrum Antiviral Program

Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory Form Joint Venture to Develop 25‑Hydroxycholesterol – A Prodrug‑Class Broad‑Spectrum Antiviral Program

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to USD 1.32 Billion, Gaining First‑in‑Class KCNT1 Ion Channel Inhibitor ABS‑1230 for Ultra‑Rare Epilepsy

Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer
CompanyDrug

Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab
CompanyDeals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Jazz Pharmaceuticals Secures Global Rights to Saniona's Epilepsy Drug SAN2355
CompanyDeals

Jazz Pharmaceuticals Secures Global Rights to Saniona’s Epilepsy Drug SAN2355

FDA Accelerates Approval of Dordaviprone for H3 K27M-Mutant Diffuse Midline Glioma
CompanyDrug

FDA Accelerates Approval of Dordaviprone for H3 K27M-Mutant Diffuse Midline Glioma

BeOne Medicines Wins Conditional Approval for Ziihera in HER2-Positive BTC
CompanyDrug

BeOne Medicines Wins Conditional Approval for Ziihera in HER2-Positive BTC

Ziihera Receives FDA Accelerated Approval for HER2-Positive Biliary Tract Cancer Treatment
CompanyMedical Device

Zymeworks and Jazz Pharmaceuticals’ Ziihera Gets Green Light for HER2+ BTC Treatment